Corvus Pharmaceuticals (CRVS) Equity Average (2022 - 2025)
Historic Equity Average for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $76.0 million.
- Corvus Pharmaceuticals' Equity Average rose 13885.6% to $76.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.0 million, marking a year-over-year increase of 13885.6%. This contributed to the annual value of $35.6 million for FY2024, which is 2483.89% down from last year.
- As of Q3 2025, Corvus Pharmaceuticals' Equity Average stood at $76.0 million, which was up 13885.6% from $64.8 million recorded in Q2 2025.
- Over the past 5 years, Corvus Pharmaceuticals' Equity Average peaked at $85.1 million during Q2 2022, and registered a low of $22.5 million during Q4 2024.
- Moreover, its 4-year median value for Equity Average was $48.0 million (2023), whereas its average is $51.6 million.
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 4579.32% in 2024, then skyrocketed by 13885.6% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Equity Average stood at $60.4 million in 2022, then crashed by 31.31% to $41.5 million in 2023, then crashed by 45.79% to $22.5 million in 2024, then skyrocketed by 237.94% to $76.0 million in 2025.
- Its last three reported values are $76.0 million in Q3 2025, $64.8 million for Q2 2025, and $40.9 million during Q1 2025.